IP Verse

Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg competitive analysis

Latest oppositions filed by Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg

Explore patent oppositions filed by Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jun 25, 2026
Patent NumberTitleApplicantOpposition Date
EP4212152
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISJan 30, 2026
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025
EP3626270
New UseNOVARTISJul 8, 2024
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISOct 9, 2023
EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 11, 2023
EP2234617
Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICADec 31, 2021
EP2981271
Therapeutic Uses Of EmpagliflozinBOEHRINGER INGELHEIMAug 12, 2019

Latest PTAB cases involving Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg

Discover the latest PTAB cases involving Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Egis Gygyszergyr Zrtkren Mkd Rszvnytrsasg with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jun 25, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
EGIS GYGYSZERGYR ZRTKREN MKD RSZVNYTRSASG7 - - -
BOEHRINGER INGELHEIM3321489
JANSSEN PHARMACEUTICA174 - 1
NOVARTIS6520 - 21